IDH1 and glioma: Despite the WHO (World Health Organization) has published a renewed classification method for gliomas by integrating histopathological results with molecular phenotypes such as IDH mutation and 1p/19q codeletion23, patients with LGGs show variable clinical prognosis even with the same diagnosis due to high heterogeneity of tumors24.